Managing XDR-TB poses several challenges, including the need for specialized healthcare facilities, the high cost of second-line drugs, and the potential for severe side effects. Additionally, ensuring patient adherence to lengthy treatment regimens is difficult but crucial to prevent further resistance development. Public health systems also face challenges in monitoring and controlling the spread of XDR-TB.
